NCT00081874 2025-04-27
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Duke University
M.D. Anderson Cancer Center